He encontrado que alguna farmacia puede tener existencias limitadas de ciertos medicamentos, mientras que otras pueden tener casi cualquier formato que se le ocurra y el habitual de dosis habitualidad apareció. En resumen, siempre se contiene el almacén de corroborar. Al mismo tiempo que el producto que más que gustaba ha resultado no estaba disponible en stock otro distinto por las Buenas costumbres también debe buscarse jefe no asн parezca. Por eso es importante disponer de un Plan B para actuar cuandod ello no ocurra. Ventaja de tomar un genérico en lugar de Asix Un genérico es más barato que el nombre de marca Uno de los mayores incentivos para someterse al Dónde comprar Lasix genérico en lugar de pagar la marca es que usted puede obtener un ahorrando importantes Lasix genérico. Por lo tanto, un Lasix genérico es en general mucho más barato que el homólogo de marca, así que una denominación genérica se hace posible para las personas que usan este medicamento con frecuencia. Un ejemplo: La compra de lurosemida en lugar de Lasix es una considerable ahorro para el presupuesto mensual de medicamentos.

Debra072706a

Tom Callaway, MD, [email protected] LODE DEBRABANDERE, FORMER BMS VICE PRESIDENT, NEUROSCIENCE,
TO LEAD AUTOIMMUNE BUSINESS UNIT AT OSIRIS THERAPEUTICS
Life Science Partner brings clinical development and
marketing talent to help launch first stem-cell therapy
ATLANTA, Georgia - July 27, 2006 - Life Science Partner announces today the recruitment of Lode Debrabandere, PhD,
former vice president, Neuroscience Business Unit of Bristol-Myers Squibb Company to Osiris Therapeutics to become
general manager of Osiris Therapeutics’ Autoimmune Diseases business unit. Osiris is a privately-held
biopharmaceutical company developing innovative technology for isolating and expanding messchymal stem cells
(MSCs) derived from donated bone marrow for therapeutic drug products.
In the past few years, Osiris has transformed from an early-stage, research-focused organization to a commercially-focused enterprise – as it prepares to complete trials and launch Prochymal in autoimmune -related disorders including the treatment of acute graft-versus-host-disease in patients receiving bone marrow transplantation, Crohn’s Disease, and other related diseases such as rheumatoid arthritis.
“Osiris fits Debrabandere like a glove,” noted Tom Callaway, MD, founder and president of Life Science Partner. “He has significant global regulatory and clinical development experience – and demonstrated global marketing strategy expertise that will accelerate the successful launch of Prochymal to help these patients.” At Bristol-Myers Squibb, Debrabandere led an interdisciplinary team to evaluate the company’s portfolio of products and programs - and then implemented a market-driven realignment of resources to expand into infectious diseases and CNS. Earlier he led U.S. marketing and global clinical development for UCB Pharma where he led the co-promotional agreements with Pfizer and Alza to rapidly grow sales of Zyrtec and Ditropan, respectively. He began his career as a trainee to the CEO of UCB Pharma before joining the global company in clinical development, rising to director of global clinical operations. A native of Belgium, Debrabandere earned his Pharm.D and PhD (Pharmaceutical Sciences) and his MBA at University of Leuven. LODE DEBRABANDERE, FORMER BMS VICE PRESIDENT, NEUROSCIENCE,
TO LEAD AUTOIMMUNE BUSINESS UNIT AT OSIRIS THERAPEUTICS
About Life Science Partner
Life Science Partner's high-quality executive, research and professional placement services target the very specific
needs of life sciences and healthcare organizations. We identify and recruit the brightest talent in the biotechnology,
pharmaceutical, medical device, academic, and healthcare services fields. Our combined scientific backgrounds and
senior management experience give us the scientific literacy and business knowledge to help us better understand
challenges, refine requirements and work more effectively with our life science clients.
For more information, call 404 920 2050 or visit http://www.lifesciencepartner.com

Source: http://lifesciencepartner.com/wp-content/uploads/2011/11/143-Osiris-Press-Release.pdf